713482-88-3 Usage
Uses
Used in Organic Synthesis:
[1-(3,4-dichlorophenyl)cyclobutyl]methylamine is used as a building block in organic synthesis for the creation of other biologically active compounds. Its unique structure allows for the development of a diverse range of molecules with potential applications in various industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [1-(3,4-dichlorophenyl)cyclobutyl]methylamine is used as a compound in research and development. Its potential role in the synthesis of new drugs makes it a valuable asset for medicinal chemistry and drug discovery efforts.
Used in Medicinal Chemistry:
[1-(3,4-dichlorophenyl)cyclobutyl]methylamine is utilized in medicinal chemistry for its potential to contribute to the discovery and design of novel therapeutic agents. Further research is necessary to fully comprehend its potential uses and optimize its application in this field.
Used in Drug Discovery:
[1-(3,4-dichlorophenyl)cyclobutyl]methylamine is also used in drug discovery processes, where its unique properties may lead to the development of new pharmaceuticals. Its potential pharmacological and toxicological properties need to be investigated to ensure safe and effective use in practical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 713482-88-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,1,3,4,8 and 2 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 713482-88:
(8*7)+(7*1)+(6*3)+(5*4)+(4*8)+(3*2)+(2*8)+(1*8)=163
163 % 10 = 3
So 713482-88-3 is a valid CAS Registry Number.
713482-88-3Relevant academic research and scientific papers
Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor
Shao, Liming,Hewitt, Michael C.,Wang, Fengjiang,Malcolm, Scott C.,Ma, Jianguo,Campbell, John E.,Campbell, Una C.,Engel, Sharon R.,Spicer, Nancy A.,Hardy, Larry W.,Schreiber, Rudy,Spear, Kerry L.,Varney, Mark A.
, p. 1438 - 1441 (2011/04/16)
The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants.
CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
-
Page/Page column 66-67; 70, (2010/11/28)
The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
